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Available online 6 May 2014Abstract The adult mammalian heart exhibits limited regenerative capacity after myocardial injury, a shortcoming that is
responsible for the current lack of definitive treatments for heart failure. A search for approaches that might enhance adult
heart regeneration has led to interest in the Hippo/Yap signaling pathway, a recently discovered signaling pathway that
regulates cell proliferation and organ growth. Here we provide a brief overview of the Hippo/Yap pathway and its known roles
in the developing and adult heart. We discuss the implications of Hippo/Yap signaling for regulation of cardiomyocyte death
and regeneration.
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Myocardial infarction (MI) is a leading cause of mortality and
morbidity. Although surgical and medical advances over the
past several decades have greatly improved survival after acute
MI (Dargie, 2005), the long term prognosis of these patients
remains poor. A major reason is the heart has limited
regenerative capacity. Because of the refractoriness of adult
cardiomyocytes to re-enter the cell cycle, the billions of
cardiomyocytes lost during acute myocardial infarction cannot
be restored, being replaced instead by fibrotic myocardial
tissue with little contractile function, poor diastolic compli-
ance, and a propensity to arrhythmia. As an adaptive response,
the surviving cardiomyocytes undergo pathological hypertro-
phic growth through activation of neurohumoral signaling
pathways. Over the long term, this adverse remodeling
following MI has a deleterious effect on cardiomyocyte function
and survival, and ultimately leads to congestive heart failure.
Current post-MI pharmacological management suppresses
neurohumoral activation that drives pathological cardiomyo-
cyte hypertrophy. Although this strategy has been success-
ful for heart failure management, clinical trial evidence with
new neurohormonal targets did not show greater salutary
effects (Mehra et al., 2003), suggesting that we are reaching
a ceiling for this approach and pinpointing the need to
develop new therapeutic targets.
One attractive strategy to improve outcome in heart failure
is to regenerate damaged myocardium by making more
functional cardiomyocytes. Extensive work over the past two
decades has overturned the prevailing dogma that adult
cardiomyocytes do not undergo cell division by demonstrating
that adult cardiomyocytes do proliferate, albeit at a low rate
(Zhou et al., 2012). Several signaling pathways have been
shown to regulate cardiomyocyte proliferation, such as IGF1
(Duerr et al., 1995), perisotin (Kuhn et al., 2007), neuregulin
(Baliga et al., 1999; Bersell et al., 2009), and fibroblast growth
factor (Engel et al., 2005). Recently, the newly defined
Hippo/Yap pathway was found to play essential roles in the
regulation of heart development and postnatal cardiomyocyte
proliferation. In this review, we summarize recent advances in
understanding the regulation of the Hippo/Yap signaling
pathway, and the role of this pathway in the developing and
adult heart. In addition, we discuss opportunities for thera-
peutic manipulation of Hippo/Yap signaling to enhance
myocardial repair and regeneration.Drosophila growth regulation by
Hippo/Yap signalingHow multicellular organisms establish and maintain prop-
er organ size is a long-standing puzzle. Genetic screens in
Drosophila for abnormal growth regulation phenotypes iden-
tified Merlin (Hamaratoglu et al., 2006), Warts (Xu et al.,
1995), Hippo (Wu et al., 2003), Salvador (Tapon et al., 2002),
Mats (Lai et al., 2005), and other mutants with similar phe-
notypes of tissue overgrowth, increased cell proliferation,
and suppressed apoptosis. The shared phenotypes of these
mutants suggested that the affected genes function in a
common pathway that regulates organ growth. Further
genetic and biochemical studies confirmed that these genesencode a kinase cascade, in which Merlin, a membrane-
associated cytoskeletal scaffolding protein, genetically func-
tions upstream of Hippo, a Ste-20 type kinase that phosphor-
ylates and activates Warts. Salvador, a WW-repeat protein,
serves as a scaffold to enhance Hippo activity (Wu et al.,
2003), while Mats, a Mob superfamily protein, interacts with
Warts to facilitate its kinase activity (Lai et al., 2005).
The missing link between the Hippo kinase cascade and
gene expression regulation was discovered by Duojia Pan's
group in 2005 (Huang et al., 2005). A yeast two hybrid screen
using Warts as the bait identified the transcriptional co-
activator Yorkie as a Warts binding protein. Follow-up ex-
periments showed that Yorkie promotes cell proliferation
and tissue growth, that its transcriptional activity is nega-
tively regulated by Hippo signaling, and that it is directly
phosphorylated by Warts. Moreover, Yorkie inactivation
blocked the tissue overgrowth phenotype of Hippo kinase
cascade mutants, indicating that phosphorylation and inac-
tivation of Yorkie is a major output of Hippo signaling.
Yorkie is a transcriptional co-activator that lacks intrinsic
DNA binding activity. The DNA binding transcription factor
Scalloped was identified as a major Yorkie partner that is
required for tissue overgrowth in Yorkie gain of function or
Hippo pathway loss of function (Zhang et al., 2008; Wu et al.,
2008; Zhao et al., 2008). Interestingly, over-expression of
Yorkie but not Scalloped caused tissue overgrowth, suggesting
that Yorkie, the protein modulated by Hippo signaling, is
limiting for tissue growth rather than Scalloped (Wu et al.,
2008).
Hippo/Yap signaling in mammals
The Hippo/Yap signaling pathway is highly conserved between
Drosophila and mammals. The mammalian orthologs of Dro-
sophila Hippo, Salvador, Warts, Mats, Yorkie and Scalloped,
are Mst1/2 (mammalian sterile twenty-like), Sav1 (Salvador-
like homolog 1), Lats1/2 (large tumor suppressor), Mob1, Yap
(YES-associated protein), and Tead1–4 (TEA domain family
member), respectively. The presence of multiple isoforms of
many of the mammalian orthologs has made their genetic
analysis in mammals complicated. In the remainder of this
review, we will use the mammal nomenclature to describe
Hippo/Yap pathway components.
Before the Hippo pathway was delineated in Drosophila,
several crucial components of the pathway had already been
cloned in mammals (Tapon et al., 2002; Xiao et al., 1991;
Sudol, 1994; Creasy and Chernoff, 1995; Tao et al., 1999). The
functions of these crucial Hippo pathway components have
been well addressed in several reviews on Tead (Pobbati and
Hong, 2013), Yap (Wang et al., 2009), and Mst (Matallanas et
al., 2008). Several excellent reviews of Hippo/Yap signaling
have also been published recently (Pan, 2007; Yu and Guan,
2013; Zhao et al., 2010). This section will focus on the recently
defined aspects of mammalian Hippo/Yap signaling (summa-
rized in Fig. 1).
Regulation of Yap in the
submembrane compartment
In response to extracellular cues and cell–cell interactions,
the Hippo kinase cascade restrains cell proliferation and
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Figure 1 The mammalian Hippo/Yap signaling pathway. Yap activity is regulated by phosphorylation, subcellular localization, and
degradation. Membrane receptors receive intracellular cues and relay them to the sub-membrane compartment. At adherens
junctions (I), E-cadherin transduces cell–cell contact information via α/β-catenin. Under conditions of high cell density, α-catenin
forms a complex with phosphorylated Yap and 14-3-3 proteins, thereby sequestering Yap. Growth factor signaling through GPCRs (II)
inhibits Lats phosphorylation of Yap through a mechanism involving Rho GTPases and actin polymerization. The classic Hippos kinase
cascade (III), containing the kinases MST1/2 (mammalian Hippo ortholog) and Lats1/2 (mammalian Warts), phosphorylates Yap to
restrain its nuclear localization and transcriptional activity. The Hippo kinase cascade is regulated by NF2 through uncharacterized
upstream receptors. Lats also phosphorylates AMOT, a Yap binding protein. Phosphorylated AMOT dissociates from F-actin and brings
bound Yap into the cytoplasm, where the complex is degraded by the ubiquitin proteasome system via interaction with AIP4. Yap is
also phosphorylated by YES/SRC (IV), under the control of uncharacterized upstream receptors. Yap is a transcriptional co-activator,
and its nuclear entry is promoted by dephosphorylation by PP2A. Nuclear Yap promotes mitogenic and anti-apoptotic gene
transcription, canonically through interaction with Tead transcription factors. Yap also enhances Wnt/β-catenin signaling through
physical interactions with β-catenin. Yap transcriptional activity is terminated by phosphorylation by a nuclear kinase, possibly
Lats1/2, leading to 14-3-3 protein binding and nuclear export.
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er, the mechanisms by which extracellular cues modulate
Hippo kinase activity are incompletely understood. Recent
work from Yin et al. partially filled this gap by elucidating
how NF2, a protein that links cytoskeletal components with
proteins in the cell membrane, controls Hippo pathway
activity (Yin et al., 2013). NF2-deficient livers had decreased
Lats and Yap phosphorylation. Mst was required for NF2-
induced Lats activation, but unexpectedly NF2 deficiency
increased Mst activity. Further biochemical studies accounted
for these observations by showing that NF2 recruits Lats to
the plasma membrane through direct binding. Sav1 similarly
recruits Mst to the plasmamembrane,where it phosphorylates
and activates Lats. Liver specific single knock of either NF2 or
Sav1 resulted in a mild increase of liver size, but double
knock-out caused massive liver overgrowth. Based on thesedata, the authors raised a “parallel model” of Hippo pathway
signal transduction, in which NF2 and Sav1 act as scaffolds to
recruit Lats and Mst, respectively, to the membrane. In the
submembrane signal transduction compartment formed by
these proteins, Mst phosphorylates and activates Lats, which
in turn phosphorylates and inhibits Yap.
The extracellular signals and their receptors that regu-
late the mammalian Hippo/Yap pathway are incompletely
understood. Yu et al. found that Yap activity is regulated
downstream of certain G-protein coupled receptors (GPCRs)
(Yu et al., 2012). Specifically, they showed that the lipids
lysophosphatidic acid (LPA) and sphingosine 1-phosphate
(S1P) stimulate Yap activity by binding to specific GPCRs
that couple to the Gα12/13 subfamily of heterotrimeric G
proteins. Gα12/13 signaling inhibited Lats activity through a
signal transduction pathway involving Rho GTPases and actin
574 Z. Lin, W.T. Pucytoskeleton organization, and independent of Mst. On the
other hand, epinephrine stimulation of the β2-adrenergic
receptor, a GPCR coupled to Gαs, enhanced Yap phosphor-
ylation and thereby inhibited Yap activity.
The Hippo kinase cascade interacts with and phosphorylates
Yap in the submembrane compartment, but Yap exerts its
main actions in the nucleus. 14-3-3 proteins, highly conserved
phosphoserine binding proteins that often bind transcription
factors (Eckardt, 2001), are crucial chaperones that mediate
proper Yap subcellular localization. In the absence of bound
targets, 14-3-3 proteins reside in the nucleus. Target protein
phosphorylation leads to 14-3-3 protein binding and export
of the protein complex from the nucleus to the cytoplasm
(Brunet et al., 2002). 14-3-3 proteins are required for Yap
nuclear export (Dong et al., 2007), but it is not clear whether
Lats is responsible for Yap phosphorylation in the nucleus.
Yap activity is regulated by cell–cell contacts, as contact
inhibition leads to Yap phosphorylation, 14-3-3 binding, and
exclusion from the nucleus. Yap interacts with α-catenin and
angiomotin (AMOT), components of intercellular junctions
which modulate Hippo/Yap signaling in response to cell–cell
interactions. α-Catenin links cadherins, calcium-dependent
intercellular adhesion molecules, with the actin cytoskeleton
at adherens junctions. In keratinocytes, α-catenin directly
interacts with 14-3-3 proteins, and the interaction is enhanced
in the presence of phospho-Yap. α-Catenin negatively regu-
lates Yap activity by recruiting it to the adherens junctions
and the submembrane region (Schlegelmilch et al., 2011).
Furthermore, the protein complex formed by α-catenin,
14-3-3 and phospho-Yap inhibits Yap dephosphorylation me-
diated by the phosphatase PP2Ac (Schlegelmilch et al., 2011).
Angiomotin (AMOT) is another intercellular junction protein
that regulates Yap activity (Zhao et al., 2011). AMOT binds to
Yap, recruiting Yap to the sub-membrane region near inter-
cellular junctions. AMOT also binds to filamentous actin
(F-actin), and this interaction is regulated by Lats, making
AMOT both a regulator and an effector of Hippo signaling.
AMOT phosphorylation dissembles it from filamentous actin
and releases it from junction complexes into the cytoplasm
(Dai et al., 2013; Chan et al., 2013). Phosphorylated AMOT
recruits the ubiquitin E3 ligase atrophin-1 interacting protein
4, leading to degradation of AMOT-bound Yap by the ubiquitin
proteasome system (Adler et al., 2013).
Actin dynamics are crucial for Hippo signal transduction,
as evidenced by the fact that inhibiting actin cytoskeleton
dynamics initiated Hippo signaling in both Drosophila and
mammalian cells (Dupont et al., 2011; Fernandez et al.,
2011). Both actin polymerization inhibitor Latrunculin B and
Rho GTPase inhibitor C3 promoted NF2 and Lats interaction
(Yin et al., 2013) and increased Lats activity (Yu et al., 2012).
How actin dynamics regulate Lats activity is an important gap
in our understanding of Hippo signal transduction. Because
the submembrane region near adherens junctions is enriched
for both Hippo pathway components and actin cytoskeleton,
this subcellular compartment is likely to be the arena in
which actin dynamics modulate Lats.
Yap/TAZ regulation of cellular proliferation
and organ size
As the crucial link between the Hippo kinase cascade and
gene transcription, Yap has been intensely studied since itsidentification as an effector of the Hippo pathway (Huang et
al., 2005). Yap has 5 HXRXXS motifs that are potential Lats1/
2 phosphorylation sites. Mutation of serine 127 to alanine
(S127A) largely abolished Mst2/Lats2-induced Yap phosphor-
ylation, 14-3-3 binding, and Yap nuclear export, indicating
that Yap S127 is the major Lats1/2 phosphorylation site
that regulates its nuclear/cytoplasmic distribution (Zhao
et al., 2007). Yap S127 phosphorylation did not directly
affect Yap and Tead interaction, but rather decreased the
interaction between Yap and Tead due Yap cytoplasmic
localization.
In the liver, overexpression of activated Yap (Yap[S127A])
for one week doubled the liver size. This dramatic effect on
organ size was due to increased proliferation and decreased
apoptosis of liver cells (Dong et al., 2007; Camargo et al.,
2007). In the cultured mammalian cells, Hippo/Yap signaling
has been shown to be central to contact inhibition: cell–cell
contacts activate Hippo to restrain Yap, thereby limiting cell
proliferation. Yap overexpression overcomes contact inhibi-
tion in a Tead-dependent manner (Zhao et al., 2007). Yap
promotes cell proliferation by stimulating the expression of
Ccna2, Ccnb1, Cdc2, Aurka, Aurkb, and Cdc25b (von Gise et
al., 2012). At the same time, Yap limits cellular apoptosis
by stimulating expression of Birc5 and Birc2 (Dong et al.,
2007).
As a vital transcriptional regulator, Yap is a nodal point
regulated by numerous upstream signaling pathways besides
the canonical Hippo kinase cascade, including the YES/SRC
tyrosine kinase pathway, the Wnt/β-catenin pathway, and
the JNK pathway. Yap was first identified as a YES-associated
protein (Sudol, 1994). In osteoblast cells, Yap directly inter-
acts with RUNX2 to suppress its transcriptional activity. The
phosphorylation of Yap by YES/SRC tyrosine kinase is required
for Yap to interact with RUNX2, as blocking YES/SRC kinase
activity abolished the interaction between these two proteins
(Zaidi et al., 2004). In tumor cells, Wnt signaling regulates Yap
expression both transcriptionally and post-transcriptionally:
in colorectal carcinoma cells, the β-catenin/TCF4 complex
directly regulated Yap expression (Konsavage et al., 2012),
while in liver cancer cells the Wnt/β-catenin downstream
target Tribbles homolog 2 (TRIB2) stabilized Yap by preventing
its degradation (Wang et al., 2013). Conversely, Yap also reg-
ulates canonical Wnt signaling by direct interaction with
β-catenin. This interaction modulates β-catenin/TCF tran-
scriptional activity (Heallen et al., 2011) and β-catenin sub-
cellular localization (Imajo et al., 2012). In a screen for
kinases that directly phosphorylate Yap, Tomlinso et al. found
that JNKs are robust Yap kinases (Tomlinson et al., 2010). This
study showed that PKCα and ERK2 also phosphorylate Yap.
These studies indicate that Yap is a key nodal point regulated
by multiple signaling pathways.Hippo/Yap pathway in the heart
The fetal heart grows primarily by expansion of cardiomyo-
cyte number (hyperplastic growth), while the postnatal heart
grows mainly by enlargement of cardiomyocytes (hypertro-
phic growth). Studies of gain and loss of function mutations in
Hippo/Yap pathway components in the heart (Table 1) have
implicated this pathway in regulating both forms of heart
growth.
Table 1 Mouse models used to study cardiac Hippo/Yap signaling.
Mouse model Organ phenotype CM size CM
apoptosis
CM
prolif.
Ref.
Hippo activation/Yap loss of function
Mst1
αMHC–Mst1,
late fetal heart
Dilated cardiomyopathy;
premature death; absence
of compensatory cardiac
hypertrophic growth.
↔ ↑ ND Yamamoto et al. (2003)
Lats2
αMHC–Lats2,
late fetal heart
Heart dysfunction, small and
dilated hearts
↓ X ND
(↑ in TAC)
Matsui et al. (2008)
Yapflox
x Nkx2.5–Cre, E7.5− Small fetal heart, fetal demise ND ND ↓ von Gise et al. (2012),
Xin et al. (2011),
Xin et al. (2013),
Del Re et al. (2013)
x Tnnt2–Cre, E7.5− Small fetal heart, fetal demise ND ↔ ↓
x αMHC–Cre, ~E12.5− Dilated, lethal cardiomyopathy
with normal
↓ ↑ ↓
CM number; impaired neonatal
and adult heart regeneration
(het; in MI) (KO or het MI) (KO or
het in MI)
(het; in MI)
Tead1
Tead1–lacZ,
constitutive knockout
Small fetal heart, fetal demise ND ND ND Chen et al. (1994)
Hippo inhibition/Yap gain of function
Sav1flox
x Nkx2.5–Cre, E7.5−x
Nkx2.5–Cre, E7.5−
Large fetal heart, postnatal
demise
↔ ↔ ↑ Heallen et al. (2011),
Heallen et al. (2013)
x αMHC–MCM, adult Normal heart function. Heart
size not reported. Extended
window for neonatal heart
regeneration; improved
outcome after MI
↓ ND ↑
Mst
Mst1/2flox x Nkx2.5–Cre,
E7.5−
Large fetal heart ND ND ND Heallen et al. (2011),
Yamamoto et al. (2003),
Odashima et al. (2007)
αMHC–DN–Mst1,
late fetal heart
Normal cardiac function;
preserved heart function
post-MI
↔ ↓ in I/R ↔ in MI
Lats2
Lats1/2flox x Nkx2.5–Cre,
E7.5−
Large fetal heart ND ND ND Heallen et al. (2011),
Matsui et al. (2008),
Heallen et al. (2013)
Lats1/2flox x
αMHC–MCM, adult
Normal heart function. Heart
size not reported. Extended
window for neonatal heart
regeneration; improved
outcome after MI.
↓ ND ↑
αMHC–DN–Lats,
late fetal heart
Biventricular hypertrophy,
normal heart function
↑ ↓ in TAC ND
Yap Gain of function
cTNT–Cre; Rosa26fs–rtTA;
ColTRE–aYAP;
Dox E8.5−
Cardiac overgrowth,
embryonic lethal.
ND ↔ ↑ von Gise et al. (2012),
von Gise et al. (2012),
Xin et al. (2011),
Xin et al. (2013)
(continued on next page)
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Table 1 (continued)
Mouse model Organ phenotype CM size CM
apoptosis
CM
prolif.
Ref.
βMHC–aYap, E9− Large fetal heart, viable
to adulthood
ND ND ↑
αMHC–aYap,
late fetal heart
Increased heart size;
Enhanced cardiac
regeneration.
↔ ↓ in MI ↑
cTNT–Cre; Rosa26fs–rtTA;
ColTRE–aYAP; Dox P0−
Increased heart size and
CM proliferation
↔ ↔ ↑
Tead1
MCK–Tead1, perinatal Age dependent heart
dysfunction and fibrosis
without cardiac
hypertrophy
ND ND ND Tsika et al. (2010)
Table summarizes mouse models reported with gain or loss of function in the Hippo kinase cascade or in Yap. Approximate stage of the
genetic manipulation is indicated based on the general properties of the promoter used. cTNT–Cre; Rosa26fs–rtTA; ColTRE–αYAP is a
cardiac-specific, Dox inducible strategy to express activated Yap (von Gise et al., 2012).
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The important role of the Hippo kinase cascade in suppress-
ing cell proliferation led Heallen, Martin, and colleagues to
hypothesize that Hippo signaling deficiency would cause
cardiac overgrowth. This hypothesis was supported by the
cardiac-restricted inactivation of Mst1/2, Sav1, and Lats2,
which resulted in markedly enlarged hearts due to increased
cardiomyocyte proliferation, trabecular expansion, and thick-
ening of the compact myocardium (Heallen et al., 2011).
However, overall cardiac structure was preserved, suggesting
a selective role of Hippo signaling in cardiac growth control.
To test the hypothesis that Yap is a critical downstream
effector of the Hippo kinase cascade in heart growth regu-
lation, our group and the Olson group studied the effect of
Yap gain or loss of function on heart development (von Gise et
al., 2012; Xin et al., 2011). As in the Hippo-deficient mutants,
overall cardiac architecture was preserved in Yap gain or loss
of function. Cardiomyocyte-specific Yap inactivation early in
heart development markedly depressed cardiomyocyte pro-
liferation and caused dramatic cardiac hypoplasia. On the
other hand, cardiomyocyte-specific expression of Yap[S127A]
enhanced cardiomyocyte proliferation and caused profound
cardiac overgrowth. The overgrowth was particularly striking
in the trabecular myocardium, which is among the first car-
diomyocyte populations to have withdrawn from the cell
cycle. These data suggest that Hippo/Yap signaling may par-
ticipate in limiting trabecular cardiomyocyte proliferation,
and that the activation of Yap is sufficient to sustain car-
diomyocyte cell cycle activity. Indeed, Yap activation in the
neonatal heart similarly delayed cardiomyocyte cell cycle
withdrawal, leading to cardiomegaly.
Tead transcription factors (Wu et al., 2008; Zhao et al.,
2008), represented by Tead1–4 in mammals, are the canon-
ical transcription factor partners of Yap. Tead1 loss of func-
tion in the germline caused mid-gestational fetal loss due to
cardiac hypoplasia (Chen et al., 1994). Yap–Tead interaction
is required for Yap mitogenic activity in cardiomyocytes, as
a peptide inhibitor of this interaction blocked Yap-driven
cardiomyocyte cell cycle re-entry in vitro (von Gise et al.,
2012). Furthermore, a Yap point mutant defective in thisinteraction (Yap S79A), failed to support normal fetal car-
diac growth (von Gise et al., 2012). Tead transcription
factors bind to the MCAT transcription factor binding motif.
This motif is associated with striated muscle genes (Yoshida,
2008), suggesting that Tead, and perhaps its partner Yap,
may have specialized roles in regulating muscle gene expres-
sion. Precedence for this possibility exists, as Drosophila
Yorkie and Scalloped have specialized roles in regulating eye
photoreceptor differentiation, independent of their growth-
promoting roles (Jukam et al., 2013).
Ongoing studies indicate that Yap regulates heart growth
and cardiomyocyte proliferation through multiple mecha-
nisms. Hippo/Yap appears to regulate Wnt signaling. Cardiac
Sav1 inactivation caused β-catenin translocation into the
nucleus and up-regulation of canonical Wnt pathway target
genes (Heallen et al., 2011). Yap was shown to physically
interact with β-catenin and to stimulate β-catenin/TCF
transcriptional activity. Moreover, β-catenin heterozygosity
suppressed the cardiac overgrowth phenotype of Hippo-
deficient embryos. In agreement with these data, transgenic
expression of activated Yap in fetal mouse hearts increased
Wnt signaling (Xin et al., 2011). A second mechanism of Yap
cardiac growth regulation involves IGF signaling. Transgenic
Yap activation stimulated the IGF signal axis, a positive reg-
ulator of cardiomyocyte proliferation, hypertrophy, and sur-
vival (Xin et al., 2011). IGF pathway activation may enhance
Wnt/β-catenin signaling, as Akt-mediated phosphorylation
and inactivation of GSK3β enhances β-catenin stability. A
third mechanism of Yap cardiac growth regulation is the
transcriptional regulation of a number of cell cycle regula-
tors. Activation of Yap in neonatal cardiomyocytes upregu-
lated cell cycle regulators, indicating that Yap directly or
indirectly stimulates expression of these cell cycle regula-
tors (von Gise et al., 2012).Hippo/Yap signaling pathway in cardiac
hypertrophy and apoptosis
Adult mammalian cardiomyocytes have limited proliferative
capacity, and thus increased size of the adult heart with
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pertrophy. In adult heart, the functions of the Hippo path-
way kinases Mst and Lats were characterized in a series of
studies carried out by the Sadoshima group, in which the
effects of increasing or decreasing kinase activity were
probed by cardiomyocyte-specific, transgenic overexpres-
sion of the candidate gene or a dominant negative mutant. In
the case of Mst1, αMHC promoter driven expression of wild
type Mst1 increased cardiomyocyte apoptosis, decreased
heart function and ventricular wall thickness, and caused
death as early as 15 days after birth (Yamamoto et al., 2003).
Overexpression of a dominant negative mutant form of Mst1
(DN-Mst1) in the heart did not affect baseline heart function,
but improved myocardial outcome after experimental MI. In
post-MI Dn-Mst1 hearts, there was reduced cardiomyocyte
apoptosis, reduced fibrosis, and preserved systolic contrac-
tion (Yamamoto et al., 2003; Odashima et al., 2007). Neither
Mst1 overexpression nor dominant negative inhibition al-
tered cardiomyocyte size. These studies demonstrate that
Mst1 activation promotes cardiomyocyte apoptosis, and
that this activation adversely affects myocardial outcome
after MI. Effects on Yap activity or cardiac regeneration were
not directly examined, and indeed Mst1 may exert its effects
through alternative pathways. For instance, cardiac Mst1
overexpression was shown to inhibit autophagy through phos-
phorylation of Beclin1 (Maejima et al., 2013).
LikeMst1 overexpression, Lats2 overexpression also caused
heart dysfunction and reduced heart size (Matsui et al., 2008).
However, the underlying mechanism appeared different, as
Lats2 overexpression did not increase baseline cardiomyocyte
apoptosis but rather reduced cardiomyocyte size. A predispo-
sition of Lats2-overexpressing cardiomyocytes to apoptosis
was unmasked by pressure overload stress induced by trans-
verse aortic constriction (TAC). Consistent with these results,
dominant negative Lats2 increased heart weight, induced
cardiomyocyte hypertrophy, and suppressed TAC-induced
apoptosis. The downstream targets phosphorylated by Lats2
that mediate these effects on cardiac growth and apoptosis
were not established in these studies. Since Yap regulates
both of these endpoints, it is likely to be essential to imple-
ment these effects of Lats2 in the heart. However, other Lats2
substrates may also play important roles. A caveat to these
experiments is the transgenic overexpression strategy, which
may lead to non-physiological effects. For example, a recent
study of adult stage, cardiac-specific Lats1/2 loss of function
showed that this genetic manipulation led to reduced cardio-
myocyte size (Heallen et al., 2013), unlike transgenic domi-
nant negative Lats2, which caused cardiomyocyte hypertrophy
(Matsui et al., 2008).
The function of Yap in postnatal cardiac hypertrophy
and apoptosis has been interrogated through genetic gain
and loss of function approaches. Two independent stud-
ies showed that late fetal cardiac Yap inactivation caused
dilated cardiomyopathy and premature death (Xin et al.,
2013; Del Re et al., 2013). Total cardiomyocyte number was
not significantly changed in Yap deficient hearts, suggesting
that the major requirement of Yap to regulate heart size
occurs early in heart development, and that myocardial hy-
poplasia was not a major cause of impaired heart function.
Yap loss of function increased cardiomyocyte apoptosis rate,
implicating pro-survival activity of Yap in postnatal cardiac
homeostasis, although these measurements were made inseverely failing hearts and it is not possible to discern if
elevated apoptosis caused, or was an effect of, cardiac
insufficiency. Del Re et al. also reported that Yap promotes
cardiomyocyte hypertrophy after MI, based on reduced car-
diomyocyte size in the remote area of post-MI hearts with
cardiac Yap haploinsufficiency (Del Re et al., 2013). How-
ever, analysis of genetic mosaics showed that Yap inactiva-
tion in a small fraction of cardiomyocytes did not change the
size of those cardiomyocytes or their hypertrophic response
to pressure overload, indicating that Yap is not cell autono-
mously required for cardiomyocyte hypertrophy in response
to pressure overload (von Gise et al., 2012). Furthermore,
Yap activation in the postnatal heart did not drive cardio-
myocyte hypertrophy (von Gise et al., 2012; Xin et al., 2013).
As with Yap overexpression, cardiac-specific Tead1 overex-
pression also did not trigger cardiac hypertrophy (Tsika et
al., 2010). These Tead1 overexpressing mice showed an age
dependent heart dysfunction phenotype, and their hearts
were extremely sensitive to pressure overload.
Taken together, we conclude that Lats may regulate
adult cardiomyocyte hypertrophy independent of Yap or
Tead1. Rather than controlling cardiac hypertrophic growth,
the canonical Hippo/Yap pathway is crucial for regulation of
cardiomyocyte survival in the adult heart. This parallels the
findings in Drosophila post-mitotic neurons, where Warts
and Lats but not Yki were required for the maintenance of
dendrites (Emoto et al., 2006). The proteins and pathways
through which Lats may regulate cardiomyocyte hypertro-
phic growth are currently unknown.Hippo/Yap in heart regeneration
The finding that Hippo/Yap signaling powerfully regulates
fetal heart growth and cardiomyocyte proliferation (von
Gise et al., 2012; Heallen et al., 2011; Xin et al., 2011), and
that Yap gain of function extends neonatal cardiomyocyte
cell cycle activity in vivo (von Gise et al., 2012) raised the
exciting possibility that this signaling pathway could be
redeployed to promote adult heart regeneration and repair.
Initial studies on the Hippo kinase cascade and Yap
suggest that this pathway remains an important regulator of
cardiomyocyte cell cycle activity in the postnatal heart,
although Yap's potency in driving cardiomyocyte prolifera-
tion wanes with cardiomyocyte maturation. We showed that
overexpression of activated Yap beginning at E8.5 dramat-
ically stimulated cardiomyocyte proliferation (von Gise et
al., 2012). In the newborn heart, Yap1 continued to drive
cardiomyocyte proliferation, although the extent of cardio-
myocyte proliferation was far less than the observed in early
heart development (von Gise et al., 2012; Xin et al., 2013).
Consistent with the stage-dependent sensitivity of cardio-
myocytes to Yap-induced proliferation, overexpression of Yap
under control of the βMHC promoter, which initiates a few
days after E8.5, resulted in less extensive cardiac overgrowth,
and these transgenic mice were viable to adulthood (Xin
et al., 2011).
The newborn mouse heart retains the ability to regener-
ate from myocardial injury, but this regenerative capacity is
lost by postnatal day 7 (P7) (Porrello et al., 2011). Given the
ability of Yap to promote neonatal cardiomyocyte prolif-
eration, Xin, Olson, and colleagues tested the ability of Yap
578 Z. Lin, W.T. Puactivation to prolong the regenerative window (Xin et al.,
2013). P7 neonatal wild type and αMHC–aYAP transgenic
mice underwent LAD ligation. Twenty-one days later, wild
type mice showed extensive scar formation, loss of myocar-
dial tissue, and ventricular dilation, while the αMHC–αYAP
mice had regenerated the infarcted myocardium with
minimal scar tissue. Consistent with these data, inactivating
Yap negative regulators Sav1 or Lats1/2 also increased car-
diomyocyte proliferation in the neonatal heart and extended
the neonatal regenerative window (Heallen et al., 2013).
These data suggest that neonatal inactivation of Hippo
pathway kinases or activation of Yap is sufficient to maintain
the proliferative competence of neonatal cardiomyocyte in
a manner that enhances neonatal cardiac regeneration.
Stimulating adult cardiomyocyte cell cycle re-entry has
proven to be far more challenging than increasing fetal car-
diomyocyte proliferation or delaying the time of neonatal
cardiomyocyte cell cycle withdrawal. Thus a crucial question
is whether or not Yap activation can promote adult heart
regeneration and stimulate adult cardiomyocyte prolifera-
tion. When 28-day old αMHC–αYap mice or wild type con-
trols were challenged with myocardial infarction (MI), Yap
transgenic mice showed better preservation of heart func-
tion and smaller scar size at 21 day post-MI (Xin et al., 2013).
αMHC–αYAP mice had 2.5-fold higher cardiomyocyte prolif-
eration compared to wild-type control post-MI. However, the
extent of adult cardiomyocyte proliferation was limited —
cardiomyocyte proliferation stimulated by expression of
activated Yap in adult cardiomyocytes was twenty-fold
lower than the rate observed in neonatal wild-type mice.
These data suggest that Yap activation in the adult heart
does promote cardiomyocyte proliferation, although the
level of proliferation may be insufficient to support mean-
ingful cardiac regeneration. Yap-dependent modulation of
other processes, such as reduction of apoptosis (Xin et al.,
2013), likely contributes to the salutary effect of Yap after
MI.
The effect of Sav1 or Lats1/2 inactivation on adult car-
diomyocyte proliferation has also been examined. Inactiva-
tion of these Hippo pathway components in the adult heart
increased cardiomyocyte DNA synthesis and karyokinesis
(Heallen et al., 2013). Qualitatively, the result was similar
to what was observed in Yap gain of function (Xin et al.,
2013). However, inactivation of Sav1 or Lats1/2 caused quan-
titatively much higher levels of cardiomyocyte cell cycle
activity (~2.5% EdU+ cardiomyocytes after 4 days of labeling).
This discrepancy may be due to the different experimental
methods used by the two groups, or it might suggest that the
Hippo pathway regulates proliferation through additional
targets other than Yap.
The contribution of resident cardiac progenitors in adult
heart homeostasis, and their potential recruitment for thera-
peutic heart regeneration, has been widely debated (Kajstura
et al., 2008; Bergmann et al., 2009; Senyo et al., 2013; Hsieh
et al., 2007). The Hippo–Yap pathway plays a critical role in
the multipotency and differentiation of embryonic stem cells,
neuronal progenitors, and intestinal stem cells (Lian et al.,
2010; Cao et al., 2008; Cai et al., 2010; Barry et al., 2013).
These data suggest that Hippo–Yap may modulate cardiac
progenitor activity. However, since most animal models used
to study the cardiac function of this pathway (Table 1), they
have primarily used cardiomyocyte-specific drivers that arepresumed to be inactive in cardiac progenitors, experimental
data on Hippo–Yap signaling in cardiac progenitors is currently
lacking. Clarifying the contribution of resident cardiac pro-
genitors to adult heart homeostasis and their potential
redeployment for therapeutic heart regeneration, and the
function of Hippo/Yap in this processes, are clearly priorities
for future studies.
Concluding comments: harnessing Hippo/Yap
for heart disease therapy
The fetal heart enlarges through hyperplastic growth. At this
developmental stage, the heart is similar with other organs,
such as liver or skin, and its size is controlled by Hippo/Yap
signaling. Shortly after birth, cardiomyocytes largely exit
the cell cycle, and the heart increases its size by hyper-
trophic rather than hyperplastic growth. The Hippo/Yap
pathway continues to influence heart size by regulating
cardiomyocyte proliferation in the newborn mice, but it has
less of an effect on adult cardiomyocyte proliferation. In
addition to cardiomyocyte proliferation, Hippo kinases also
regulate cardiac hypertrophic growth. Hippo/Yap signaling
also influences cardiomyocyte autophagy and apoptosis.
The studies summarized in this review demonstrate
the importance of the Hippo/Yap pathway in the regulation
of heart growth during fetal development. Modulation of
this pathway in the neonatal heart prolongs the neonatal
regenerative window, highlighting the potential for enhanc-
ing cardiac regeneration. Yap activation in the injured adult
heart is also beneficial at least in the short-term, although
stimulation of cardiomyocyte proliferation was modest and
additional mechanisms are also likely to contribute. Over the
past two decades, many paracrine factors and their path-
ways have been found to stimulate cardiomyocyte prolifer-
ation, such as IGF1 (Duerr et al., 1995), perisotin (Kuhn et al.,
2007), neuregulin (Baliga et al., 1999; Bersell et al., 2009),
and fibroblast growth factor (Engel et al., 2005). However,
these agents also cause cardiomyocyte hypertrophy (Baliga
et al., 1999; McMullen et al., 2004; House et al., 2010; Oka et
al., 2007), which may be deleterious to heart function in the
long run. When compared with the other signaling pathways
involved in cardiac repair, the Hippo/Yap pathway stands out
by promoting cardiomyocyte proliferative growth and en-
hancing myocardial recovery after MI without stimulating
cardiomyocyte hypertrophy.
A number of major questions remain, and the answers have
important implications for our understanding of adult cardio-
myocyte homeostasis and the therapeutic potential of Hippo/
Yap pathway modulation for cardiac repair and regeneration.
Why does Yap stimulation of cardiomyocyte prolifera-
tion wane from fetal to neonatal to adult heart? One pos-
sibility is that Yap activation alone is insufficient to overcome
the multiple barriers to postnatal cardiomyocyte cell cycle
activity. Another possibility is that unknown factors block
Yap activity in the adult heart. Future work addressing this
question may further our understanding of Hippo/Yap path-
way regulation and allow us to develop strategies to augment
Yap-driven cardiac regeneration regulation.
Why does inactivation of Yap in the late fetal heart cause
progressive, lethal dilated cardiomyopathy? Does this reflect
a developmental defect that becomes expressed postnatally,
579Hippo/YAP1 signaling and applications to heart regeneration and rejuvenationor an ongoing requirement for Yap in the maintenance of
adult heart function? Current data from the failing adult
heart suggests that Yap is required to suppress cardiomyo-
cyte apoptosis. However, cardiomyocyte number in these
failing hearts was not detectably reduced. Perhaps Yap has
additional roles in the postnatal cardiomyocyte, as it does in
the Drosophila eye (Jukam et al., 2013).
Finally, a prerequisite to considering modulation of the
Hippo/Yap pathway for therapeutic cardiac regeneration is a
demonstration that this can be done without induction of
tumors, since activation of Yap is highly oncogenic in pro-
liferative tissues such as skin or liver. Presently, the long
term safety of Yap activation in cardiomyocytes has not been
reported. Furthermore, approaches need to be developed to
stimulate Yap in cardiomyocytes and not in other tissues or
organs. This might be achieved by the identification of
beneficial downstream genes regulated by Hippo/Yap, which
may yield more cardiac-selective drug targets. Alternatively,
localized or cell-type specific drug or gene delivery technol-
ogies may be used to achieve cardiomyocyte-specific Yap
activation.
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